Beung‐Chul Ahn

Abstract 5964: Single-cell multi-omics profiling unveils the regulatory mechanisms of small cell lung cancer

C. G. Park, Namhee Yu, Junghyun Kim, Se Hwa Hong et autres

Abstract Small cell lung cancer (SCLC) is a highly aggressive lung cancer with an extremely poor prognosis. The mechanisms underlying its tumor progression and therapeutic strategies remain poorly understood. To address this clinical challenge, we utilized single-cell ATAC-RNA multiomic profiling to investigate …

kr (code pays fourni par la source)

Consensus Statement on ctDNA Minimal Residual Disease Testing in Early Stage NSCLC: A Delphi Study by the Asian Thoracic Oncology Research Group

Aaron C. Tan, Bin-Chi Liao, Molly Li, David J Lee et autres

INTRODUCTION: Minimal residual disease (MRD) detection using liquid biopsy is an emerging tool for risk stratification and monitoring for recurrence in resected early stage NSCLC. There is increasing need for clear guidance on its optimal clinical implementation. METHODS: The Asian Thoracic Oncology …

sg, tw, hk, my, jp, th, cn, au, us, kr (code pays fourni par la source)

Upfront EGFR TKI-Based Treatment for Unresectable Stage III EGFR-Mutant NSCLC (KCSG-LU25-04): A Multicenter Retrospective Comparative Study

Jinyong Kim, Beung‐Chul Ahn, Jeongmin Seo, Keon Uk Park et autres

us, kr (code pays fourni par la source)

Preoperative chemoradiotherapy plus pembrolizumab for esophageal squamous cell carcinoma (ACTS-29)

Min Hee Hong, Sung Kwan Shin, Sujin Choi, Beung‐Chul Ahn et autres

kr, us (code pays fourni par la source)

Lorlatinib in Tyrosine Kinase Inhibitor−Naive Advanced ROS1 -Positive Non−Small Cell Lung Cancer

Beung‐Chul Ahn, Yu Jung Kim, Young Ju Lee, Koung Jin Suh et autres

Importance: ROS1 rearrangement is rare but is an attractive therapeutic target in advanced non-small cell lung cancer (NSCLC). Crizotinib, entrectinib, and repotrectinib have been approved by the US Food and Drug Administration for treatment of ROS1-positive NSCLC. Lorlatinib, a brain-penetrant, third-generation tyrosine …

us, kr (code pays fourni par la source)

408 Treatment patterns and clinical outcomes of patients with resectable NSCLC receiving neoadjuvant immunochemotherapy with or without adjuvant immunotherapy: a real-world single-center study

Young Joo Lee, Ji‐Youn Han, Beung‐Chul Ahn

Background Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery alone for resectable non-small-cell lung cancer (NSCLC). Recently, novel neoadjuvant immunochemotherapy, with or without adjuvant therapy, became standard for resectable NSCLC, but real-world data remain limited. This study assessed real-world treatment …

kr (code pays fourni par la source)

2624P Artificial intelligence (AI)-powered immune phenotype (IP) predicts differential benefit from nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) in advanced clear cell renal cell carcinoma (ccRCC)

C.G. Kim, Minkyu Jung, Jae‐Hun Kim, Hee Sang Hwang et autres

kr (code pays fourni par la source)

VEGF Signal Complexity Confers Resistance to Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in EGFR‐Tyrosine Kinase Inhibitor‐Resistant Non‐Small Cell Lung Cancer

Se Hwa Hong, Namhee Yu, Ju Young Cho, Geon Kook Lee et autres

ABSTRACT Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) therapy is beneficial for epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI)‐resistant non‐small cell lung cancer (NSCLC); however, the resistance mechanisms are not fully understood. In this study, we conducted a single‐cell RNA‐sequencing analysis of EGFR‐TKI‐resistant …

us, kr (code pays fourni par la source)

Longitudinal pharmacogenomic analysis of refractory lung cancer to identify therapeutic candidates for epidermal growth factor receptor–tyrosine kinase inhibitor resistance subclones

Namhee Yu, Mihwa Hwang, Beung‐Chul Ahn, Youngjoo Lee et autres

Abstract The dynamic nature of longitudinal tumor evolution across patients presents challenges in designing effective drugs. Here we aimed to determine tumor evolution resistance mechanisms and explore candidate drugs for specific tumor evolution types. We conducted longitudinal pharmacogenomic analysis of datasets of …

kr (code pays fourni par la source)

A conserved pilin from uncultured gut bacterial clade TANB77 enhances cancer immunotherapy

Chan Yeong Kim, Dong Jin Park, Beung‐Chul Ahn, Seungbyn Baek et autres

Immune checkpoint blockade (ICB) has become a standard anti-cancer treatment, offering durable clinical benefits. However, the limited response rate of ICB necessitates biomarkers to predict and modulate the efficacy of the therapy. The gut microbiome’s influence on ICB efficacy is of particular …

kr, de, us (code pays fourni par la source)

A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)

Dong Ki Lee, Sook Ryun Park, Yeul Hong Kim, Yun‐Gyoo Lee et autres

Spartalizumab (PDR001) is a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1). We conducted a single-arm, phase 2 trial to investigate the efficacy and safety of spartalizumab in patients with refractory esophageal squamous cell carcinoma (ESCC). Patients with histologically …

kr (code pays fourni par la source)

Blood Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Promising Screening Biomarkers for Brain Metastases in Patients with Lung Cancer

Su‐Hyun Kim, Beung‐Chul Ahn, Dong-Eun Lee, Ki Hoon Kim et autres

The diagnosis of brain metastases (BMs) in patients with lung cancer (LC) predominantly relies on magnetic resonance imaging (MRI), a method that is constrained by high costs and limited accessibility. This study explores the potential of serum neurofilament light chain (sNfL) and …

kr (code pays fourni par la source)